Feature | Cath Lab | May 07, 2018| Simon Trinh and Jeffrey Wong

Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology Market

Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Major mergers in interventional cardiology.

Major mergers in interventional cardiology.

The European interventional cardiology market is currently valued at nearly $1.4 billion. This is a mature market that has been in decline for many years as a result of market-wide factors, such as lack of innovation, consistent price erosion and increased competition. In recent years, the interventional cardiology market has been experiencing a period of consolidation, whereby large competitors are entering new market segments organically or through strategic mergers and acquisitions. This has resulted in tremendous downward pricing pressure, as consolidated companies have more power to bundle various devices at a discount in order to win tenders and contract offers with hospitals and labs.

Recent Mergers and Acquisition in Interventional Cardiology
A closer analysis of recent market transactions reveals that deals are, on average, becoming increasingly large in size. This trend is not unique to interventional cardiology markets and is prevalent in other mature medical device markets as well. Market segments that are smaller in size — like vascular closure devices, optical coherenace tomography (OCT) catheters and fractional flow reserve (FFR) guidewires — will be affected the most by recent market transactions. Recent cardiology mergers include:

Philips Acquires Spectranetics, Expanding its Image-guided Therapy Device Offerings

Abbott Completes Acquisition of St. Jude Medical

Teleflex to Acquire Vascular Solutions

Philips Acquires Volcano for $1 Billion to Expand Position in Interventional Lab Market



VCD Market Has the Greatest Downside
The vascular closure devices (VCD) market segment is expected to be amongst the most negatively affected in the market, as the anticipated price erosion will outpace growth in sales volume. In addition, there has been a continual drop in the rate of complications with VCDs, mainly due to doctors becoming selective in the way that they use closure devices. This benefits physicians and patients but reduces vascular closure device sales and the market, overall.

Read the article "Advances and Trends in Vascular Closure Devices."


FFR Guidewire Market Benefiting From Price Erosion
The FFR guidewire market segment is expected to be the fastest-growing in the European interventional cardiology market, as price erosions will lead to even greater increases in device adoption and, therefore, unit sales. In addition, St. Jude Medical (now Abbott) recently released the PressureWire X Guidewire, which has demonstrated improved outcomes with complex anatomies, allowing physicians the option to use FFR guidewires in a wider range of patients.  Furthermore, new companies are expected to enter this market in the coming years, which will lead to more research and development in the area.

Read the article "What is New in FFR Technology."



OCT Catheter Market
The OCT catheter market segment will also see an increase in market value, due to increased competition and adoption rates. Until recently, St. Jude Medical was the only competitor in the space and in 2017 the company was acquired by Abbott. Terumo is also gaining progress in this space with the Fastview OCT catheter. Increased competition in this market is healthy and will likely result in more research and development. In addition, adoption rates are expected to increase across Europe, due to growing awareness of the advantages of OCT, such as assisting in optimum stent placement locations and verifying correct stent deployment.

Read the article "Read the article "Optical Coherence Topography Offers Superior Resolution in Coronary Stent Implantation."

In conclusion, despite lackluster growth across the majority of the market, certain devices, such as FFR guidewires and OCT catheters, are expected to exhibit strong growth over the next several years. These markets have been affected by some major market transactions recently and will experience faster rates of price erosion, due to product bundling. However, unit sales growth will ultimately exceed price declines and lead to overall market growth for these two markets.

Editor's note: Simon Trinh is a senior research analyst at iData Research. He was the lead researcher on the latest research covering the interventional cardiology market in Europe. Jeff Wong is the analyst director at iData Research. He has been involved in numerous cardiology market research projects and now leads a team involved in that market and many others. For more information idataresearch.com.


1. European Market Report Suite for Interventional Cardiology Devices Market 2018 – MedSuite, iData Research Inc.


Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init